GT Biopharma (GTBP) Interest & Investment Income (2018 - 2026)
GT Biopharma (GTBP) posted quarterly Interest & Investment Income of $67000.0 for Q1 2026, up 109.38% year-over-year from $32000.0 in Q1 2025, and up 294.12% quarter-over-quarter from $17000.0 in Q4 2025.
GT Biopharma (GTBP) Interest & Investment Income (2018 - 2026) Analysis & Trends
GT Biopharma (GTBP) has reported Interest & Investment Income for 6 consecutive years, with $67000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income rose 109.38% year-over-year to $67000.0; the TTM figure through Mar 2026 stood at $158000.0 (down 45.89% YoY), while the FY2025 annual figure was $123000.0, down 69.4% from the prior year.
- Interest & Investment Income advanced to $67000.0 in Q1 2026 per GTBP's latest filing, from $17000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $220000.0 in Q4 2023 and bottomed at $17000.0 in Q4 2025.
- Historically, Interest & Investment Income has averaged $99333.3 across 4 years, with a median of $81500.0 in 2024.
- Annual changes were most pronounced in 2025 — Interest & Investment Income plunged 77.46% — and 2026, when it surged 109.38%.
- GT Biopharma's Interest & Investment Income stood at $220000.0 in 2023, then tumbled by 73.18% to $59000.0 in 2024, then tumbled by 71.19% to $17000.0 in 2025, then jumped by 294.12% to $67000.0 in 2026.
- Business Quant data shows GTBP's Interest & Investment Income at $67000.0 in Q1 2026, $17000.0 in Q4 2025, and $36000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 28.14 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 10.98 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 5.13 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 115.94 Mn |
| 10 | GT Biopharma | 8.38 Mn | 8.38 Mn | - | 67,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 67,000.00 |
| Dec 31, 2025 | 17,000.00 |
| Sep 30, 2025 | 36,000.00 |
| Jun 30, 2025 | 38,000.00 |
| Mar 31, 2025 | 32,000.00 |
| Dec 31, 2024 | 59,000.00 |
| Sep 30, 2024 | 96,000.00 |
| Jun 30, 2024 | 105,000.00 |
| Mar 31, 2024 | 142,000.00 |
| Dec 31, 2023 | 220,000.00 |
| Sep 30, 2023 | 216,000.00 |
| Mar 31, 2023 | 164,000.00 |
| Dec 31, 2021 | 6,000.00 |
| Sep 30, 2021 | 32,000.00 |
| Dec 31, 2018 | -1,000.00 |
| Sep 30, 2018 | -228.51 Mn |